Open AccessBiology drives the discovery of bispecific antibodies as innovative therapeutics
Author(s) -
Siwei Nie,
Zhuozhi Wang,
María Moscoso-Castro,
Paul D'Souza,
Can Lei,
Jianqing Xu,
Jijie Gu
Publication year - 2020
Publication title -
antibody therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.579
H-Index - 5
ISSN - 2516-4236
DOI - 10.1093/abt/tbaa003
Subject(s) - bispecific antibody , computational biology , antibody , drug discovery , biology , neuroscience , medicine , immunology , bioinformatics , monoclonal antibody
A bispecific antibody (bsAb) is able to bind two different targets or two distinct epitopes on the same target. Broadly speaking, bsAbs can include any single molecule entity containing dual specificities with at least one being antigen-binding antibody domain. Besides additive effect or synergistic effect, the most fascinating applications of bsAbs are to enable novel and often therapeutically important concepts otherwise impossible by using monoclonal antibodies alone or their combination. This so-called obligate bsAbs could open up completely new avenue for developing novel therapeutics. With evolving understanding of structural architecture of various natural or engineered antigen-binding immunoglobulin domains and the connection of different domains of an immunoglobulin molecule, and with greatly improved understanding of molecular mechanisms of many biological processes, the landscape of therapeutic bsAbs has significantly changed in recent years. As of September 2019, over 110 bsAbs are under active clinical development, and near 180 in preclinical development. In this review article, we introduce a system that classifies bsAb formats into 30 categories based on their antigen-binding domains and the presence or absence of Fc domain. We further review the biology applications of approximately 290 bsAbs currently in preclinical and clinical development, with the attempt to illustrate the principle of selecting a bispecific format to meet biology needs and selecting a bispecific molecule as a clinical development candidate by 6 critical criteria. Given the novel mechanisms of many bsAbs, the potential unknown safety risk and risk/benefit should be evaluated carefully during preclinical and clinical development stages. Nevertheless we are optimistic that next decade will witness clinical success of bsAbs or multispecific antibodies employing some novel mechanisms of action and deliver the promise as next wave of antibody-based therapeutics.